Skip to main content
. 2022 May 9;39(7):3131–3145. doi: 10.1007/s12325-022-02148-8

Fig. 2.

Fig. 2

a SELENA-SLEDAI and PGA scores by disease activity patterns over the observation period and b organ manifestations by SELENA-SLEDAI domains over the observation period by disease activity pattern. ***p < 0.001 MSK-CA vs MSK-RR; **p < 0.01 MSK-CA vs MSK-RR; *p < 0.05 MSK-CA vs MSK-RR; †††p < 0.001 MSK-CA vs MSK-LQ; ††p < 0.01 MSK-CA vs MSK-LQ; p < 0.05 MSK-CA vs MSK-LQ; ###p < 0.001 MSK-RR vs MSK-LQ; ##p < 0.001 MSK-RR vs MSK-LQ; and #p < 0.05 MSK-RR vs MSK-LQ. CA chronically active, LQ long quiescence, MSK musculoskeletal, PGA Physician Global Assessment, RR relapsing–remitting, SELENA SLEDAI Safety of Estrogens in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index